NUTLEY, N.J. , March 25, 2025 /PRNewswire/ -- Eisai Inc.
announced today that the company will present the latest findings from its robust neurology portfolio, including data on real-world experience and continued maintenance dosing with our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI ® ) at the American Academy of Neurology (AAN) Annual Meeting, being held in San Diego, California , and virtually from April 5-9 .
Eisai will present two (2) oral presentations and seven (7) posters on lecanemab and the insomnia dual orexin receptor antagonist DAYVIGO ® (lemborexant) CIV. Lecanemab Real World Experience Presentations On Wednesday, April 9 , as part of Poster Session P12, "Aging, Dementia, and Behavioral Neurology: Alzheimer's Treatment" ( 11:45 AM - 12:45 PM PT ), two posters will be presented on real-world experience with lecanemab, including results on efficacy and safety in the clinical setting and patient satisfaction with their treatment experience: Oral Presentations Oral presentations include results on lecanemab maintenance dosing, which supports the need for continued treatment of this chronic, progressive disease. Additionally, a cost-effective analysis of lecanemab in Canada will be presented.
"The data presented at AAN highlights not only the breadth and depth of real-world experience with lecanemab compared to clinical trials, but also the importance of.
